There's a classic scene in Margin Call where the boss looks at the junior analyst and says: "Explain it to me like I'm a child." Well, that's exactly what I'm going to do with DocGo's (DCGO) fourth quarter 2025 results, because what came out of that earnings call deserves to be translated from corporate doublespeak into plain human language.
The Damage in Numbers
DocGo — for those unfamiliar, a company that promises to revolutionize mobile healthcare with ambulances, telehealth, and medical transport services — dropped its Q4 2025 numbers on Monday, March 16, 2026.
And the result? A punch in the face to anyone still holding this position on hope alone.
Revenue: $74.94 million. A 37.98% drop year over year. You read that right. Nearly a 38% nosedive on the top line. Sure, it beat consensus by a measly $4.58 million, but — come on — when revenue craters almost 40% and the market celebrates because it "beat estimates," that's the equivalent of celebrating that the Titanic sank slower than expected.
Earnings per share (EPS): -$0.46. Negative. And it missed analyst estimates by $0.36. Meaning the market expected a $0.10 loss and got slapped with something nearly five times worse.
Pause to let that sink in.
The Context Nobody's Talking About
DocGo rode a golden wave during and right after the pandemic. Fat contracts with New York City to house and treat migrants, mass vaccination services, explosive demand for mobile health. The stock became a darling of small-cap funds.
But here's the lesson Nassim Taleb would hammer into your skull: revenue concentrated in temporary government contracts is fragility dressed up as growth. When the contracts dry up — and they always dry up — what's left?
What's left is a company desperately trying to pivot toward recurring, sustainable revenue, burning cash in the process, with the bottom line plunging deep into the red.
CEO Lee Bienstock and CFO Norman Rosenberg did the usual dance on the call — "forward-looking statements," "we're confident in the pipeline," "growth opportunities" — the script every CEO reads when the numbers are ugly and they need to keep the institutional investors in their seats. It's the corporate theater we all know by heart.
What the Analysts Asked (and What They Really Wanted to Know)
The call featured names like Deutsche Bank, Needham, BTIG, Cantor Fitzgerald, and Stifel. Serious people asking questions that basically boiled down to: "Where are you going to find revenue to replace what you lost?"
And that is the question.
Because the mobile health market is real. DocGo's thesis isn't absurd. Bringing medical care to the patient instead of dragging the patient to the hospital makes economic and clinical sense. But between a good thesis and a good company there's a chasm called execution — and Q4 2025 showed that chasm is wide.
The Reflection That Actually Matters
Benjamin Graham said that in the short run the market is a voting machine, but in the long run it's a weighing machine. DocGo is at a moment where the votes are fleeing, and the weight on the scale is shrinking quarter after quarter.
The stock trades like a classic value trap — "it's cheap," say the optimists. But cheap relative to what? Revenue in freefall? Earnings that don't exist?
If you have money in this stock, you need to ask yourself with brutal honesty: Am I investing in a thesis that will prove out over the next 12-18 months, or am I doing what the gambler does at the casino — doubling down after a loss?
Because in the market, unlike the casino, nobody offers you a free drink while you lose everything.
Skin in the game or one foot out the door. Pick one.
